<?xml version="1.1" encoding="utf-8"?>
<rdf:RDF xmlns:OMEXlib="http://omex-library.org/"
   xmlns:bqbiol="http://biomodels.net/biology-qualifiers/"
   xmlns:bqmodel="http://biomodels.net/model-qualifiers/"
   xmlns:dc="http://purl.org/dc/terms/"
   xmlns:foaf="http://xmlns.com/foaf/0.1/"
   xmlns:local="http://omex-library.org/NewOmex.omex/NewModel.rdf#"
   xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
  <rdf:Description rdf:about="http://omex-library.org/BIOMD0000000536.omex">
    <bqmodel:isDescribedBy rdf:resource="local:00001"/>
    <ns1:keyword xmlns:ns1="http://prismstandard.org/namespaces/basic/2.0/">Biomodels</ns1:keyword>
    <ns2:description xmlns:ns2="http://purl.org/dc/elements/1.1/">&lt;body xmlns="http://www.w3.org/1999/xhtml"&gt;
  &lt;div class="dc:title"&gt;Dwivedi2014 - Crohns IL6 Disease model -
sgp130 activity&lt;/div&gt;
  &lt;div class="dc:description"&gt;This model is comprised of four models:
&lt;br/&gt;
  &lt;ul&gt;
    &lt;li&gt;
      &lt;a href="http://www.ebi.ac.uk/biomodels-main/BIOMD0000000534"&gt;[BIOMD0000000534]&lt;/a&gt;
  Healthy Volunteer model
  &lt;br/&gt;&lt;/li&gt;
      &lt;li&gt;
        &lt;a href="http://www.ebi.ac.uk/biomodels-main/BIOMD0000000535"&gt;[BIOMD0000000535]&lt;/a&gt;
  Crohn&amp;apos;s Disease - IL-6 Antibody
  &lt;br/&gt;&lt;/li&gt;
        &lt;li&gt;
          &lt;a href="http://www.ebi.ac.uk/biomodels-main/BIOMD0000000536"&gt;[BIOMD0000000536]&lt;/a&gt;
  Crohn&amp;apos;s Disease - sgp130FC&lt;/li&gt;
          &lt;li&gt;
            &lt;a href="http://www.ebi.ac.uk/biomodels-main/BIOMD0000000537"&gt;[BIOMD0000000537]&lt;/a&gt;
  Crohn&amp;apos;s Disease - IL-6Ra Antibody
  &lt;br/&gt;&lt;/li&gt;
          &lt;/ul&gt;Possible avenues for Interleukin-6 (IL-6) inhibition in
treating Crohn&amp;apos;s disease are compared here. Each model refers to
separate ligands. The system simulates differential activity of the
ligands on the signalling of IL-6. 
&lt;span class="st"&gt;This affects Signal Transducer and Activator of
Transcription 3&lt;/span&gt; (STAT3) activity on the production of
biomarker C-Reactive Protein (CRP) expression.
&lt;br/&gt;The figure referring to this Crohn&amp;apos;s Disease model is 6b.
&lt;br/&gt;&lt;/div&gt;
          &lt;div class="dc:bibliographicCitation"&gt;
            &lt;p&gt;This model is described in the article:&lt;/p&gt;
            &lt;div class="bibo:title"&gt;
              &lt;a href="http://identifiers.org/pubmed/24402116" title="Access to this publication"&gt;A multiscale model of
    interleukin-6-mediated immune regulation in Crohn&amp;apos;s disease and
    its application in drug discovery and development.&lt;/a&gt;
            &lt;/div&gt;
            &lt;div class="bibo:authorList"&gt;Dwivedi G, Fitz L, Hegen M, Martin
  SW, Harrold J, Heatherington A, Li C.&lt;/div&gt;
            &lt;div class="bibo:Journal"&gt;CPT Pharmacometrics Syst Pharmacol
  2014; 3: e89&lt;/div&gt;
            &lt;p&gt;Abstract:&lt;/p&gt;
            &lt;div class="bibo:abstract"&gt;
              &lt;p&gt;In this study, we have developed a multiscale systems model
    of interleukin (IL)-6-mediated immune regulation in Crohn&amp;apos;s
    disease, by integrating intracellular signaling with
    organ-level dynamics of pharmacological markers underlying the
    disease. This model was linked to a general pharmacokinetic
    model for therapeutic monoclonal antibodies and used to
    comparatively study various biotherapeutic strategies targeting
    IL-6-mediated signaling in Crohn&amp;apos;s disease. Our work
    illustrates techniques to develop mechanistic models of disease
    biology to study drug-system interaction. Despite a sparse
    training data set, predictions of the model were qualitatively
    validated by clinical biomarker data from a pilot trial with
    tocilizumab. Model-based analysis suggests that strategies
    targeting IL-6, IL-6R?, or the IL-6/sIL-6R? complex are less
    effective at suppressing pharmacological markers of Crohn&amp;apos;s
    than dual targeting the IL-6/sIL-6R? complex in addition to
    IL-6 or IL-6R?. The potential value of multiscale system
    pharmacology modeling in drug discovery and development is also
    discussed.CPT: Pharmacometrics &amp;amp; Systems Pharmacology
    (2014) 3, e89; doi:10.1038/psp.2013.64; advance online
    publication 8 January 2014.&lt;/p&gt;
            &lt;/div&gt;
          &lt;/div&gt;
          &lt;div class="dc:publisher"&gt;
            &lt;p&gt;This model is hosted on 
  &lt;a href="http://www.ebi.ac.uk/biomodels/"&gt;BioModels Database&lt;/a&gt;
  and identified by: 
  &lt;a href="http://identifiers.org/biomodels.db/BIOMD0000000536"&gt;BIOMD0000000536&lt;/a&gt;.&lt;/p&gt;
            &lt;p&gt;To cite BioModels Database, please use: 
  &lt;a href="http://identifiers.org/pubmed/20587024" title="Latest BioModels Database publication"&gt;BioModels Database:
  An enhanced, curated and annotated resource for published
  quantitative kinetic models&lt;/a&gt;.&lt;/p&gt;
          &lt;/div&gt;
          &lt;div class="dc:license"&gt;
            &lt;p&gt;To the extent possible under law, all copyright and related or
  neighbouring rights to this encoded model have been dedicated to
  the public domain worldwide. Please refer to 
  &lt;a href="http://creativecommons.org/publicdomain/zero/1.0/" title="Access to: CC0 1.0 Universal (CC0 1.0), Public Domain Dedication"&gt;CC0
  Public Domain Dedication&lt;/a&gt; for more information.&lt;/p&gt;
          &lt;/div&gt;
        &lt;/body&gt;</ns2:description>
    <ns3:title xmlns:ns3="http://purl.org/dc/elements/1.1/">A multiscale model of interleukin-6-mediated immune regulation in Crohn's disease and its application in drug discovery and development</ns3:title>
  </rdf:Description>
  <rdf:Description rdf:about="local:00001">
    <ns4:identifier xmlns:ns4="http://purl.org/dc/elements/1.1/"
       rdf:resource="http://identifiers.org/doi/10.1038/psp.2013.64"/>
    <ns5:label xmlns:ns5="http://www.w3.org/2000/01/rdf-schema#">G Dwivedi, L Fitz, M Hegen, SW Martin, J Harrold, A Heatherington &amp; C Li. A multiscale model of interleukin-6-mediated immune regulation in Crohn's disease and its application in drug discovery and development. CPT: Pharmacometrics &amp;amp; Systems Pharmacology 3, 1 (2014).</ns5:label>
  </rdf:Description>
</rdf:RDF>

